MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Subscribe To Our Newsletter & Stay Updated
